| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | tenofovir disoproxil fumarate (Viread®) |
| Formulation | 33 mg/g granules |
| Reference number | 1938 |
| Indication | In combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adults for whom a solid dosage form is not appropriate. Treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with: compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis; decompensated liver disease |
| Company | Gilead Sciences Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 17/01/2013 |